Pfizer’s/GSK’s ViiV Healthcare Receives EU Approval for HIV Drug

ViiV Healthcare, a specialist HIV company of Pfizer, GlaxoSmithKline (GSK), and Shionogi, has received marketing authorization from the European Commission for Triumeq, a once-daily, single pill, combination therapy to treat HIV. The drug was approved by the US Food and Drug Administration in August 2014.

Triumeq (dolutegravir 50 mg / abacavir 600 mg / lamivudine 300 mg) tablets was approved for treating HIV in adults and adolescents aged 12 years and older and weighing at least 40 kg. The combination therapy consists of the integrase strand transfer inhibitor,  dolutegravir, with the nucleoside reverse transcriptase inhibitors, abacavir and lamivudine. Dolutegravir was the first drug approved from Viiv Healthcare; it was approved in the US in August 2013 and in Europe in January 2014 under the brand name Tivicay.

In June 2014, ViiV Healthcare formed an agreement with Janssen R&D Ireland Ltd for developing and commercializing a single-tablet combining dolutegravir, the active ingredient in Tivicay, and Janssen's non-nucleoside reverse transcriptase inhibitor,rilpivirine, the active ingredient in Edurant. The deal represented ViiV Healthcare's first external collaboration to develop a single-tablet regimen with another company's branded product.

ViiV Healthcare was established in November 2009 by GSK and Pfizer with a specific focus on HIV treatments.Shionogi joined as a shareholder in October 2012.

Source: GlaxoSmithKline

Leave a Reply

Your email address will not be published. Required fields are marked *